Treatment of Mild-to-Moderate COVID-19 Pneumonia in Ambulatory Patients at High Risk for Progression to Severe Disease
This protocol covers the ambulatory patient who remains stable on room air — oxygen saturation above 94%, no supplemental oxygen required — yet carries risk factors that place them at meaningful risk of deteriorating to severe COVID-19.
Clinical Scenario
Ambulatory patient with mild-to-moderate COVID-19. SpO₂ is maintained above 94% on room air; supplemental oxygen is not currently needed. Despite apparent stability, the patient is identified as high risk for progression to severe disease.
Treatment Approach
The protocol addresses an antiviral treatment strategy initiated early in the course of illness. An alternative approach is specified for patients who are immunocompromised. The timing window from symptom onset is a defining constraint of eligibility.
References
DOI: 10.1093/cid/ciac724
In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.
Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.
In ambulatory patients (≥18 years) with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options, the IDSA guideline panel suggests molnupiravir initiated within 5 days of symptom onset rather than no molnupiravir.
Molnupiravir 800 mg for 5 days.
If other treatment options are not available then consider molnupiravir for 5 days (oral) or, if immunocompromised, high-titer convalescent plasma (intravenous) with activity against circulating variant.
View source ↗